Filing
2nd Quarter - Report
Lobbying activity
4
Patent Thickets, Interchangeability of biosimilars, Clinical Trials exemption for biosimilars, "Net Effective Cost" PBM reform, Country of Origin labeling, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
Incentivizing domestic manufacturing of essential medicines.